Abstract
Childhood ependymomas, which comprise approximately 10% to 15% of all brain tumors arising in patients less than 18 years of age, remain a highly problematic group of tumors to treat. Relapse-free survival rates vary significantly in contemporary series, and therapeutic approaches remain unsettled.